Dose-Finding Based on Efficacy-Toxicity Trade-Offs
From MaRDI portal
Publication:70261
DOI10.1111/j.0006-341x.2004.00218.xzbMath1274.62883WikidataQ45038149 ScholiaQ45038149MaRDI QIDQ70261
John D. Cook, Peter F. Thall, John D. Cook, Peter F. Thall
Publication date: 27 August 2004
Published in: Biometrics (Search for Journal in Brave)
Applications of statistics to biology and medical sciences; meta analysis (62P10) Bayesian inference (62F15)
Related Items (36)
Optimizing the Concentration and Bolus of a Drug Delivered by Continuous Infusion ⋮ Novel Bayesian Adaptive Designs and Their Applications in Cancer Clinical Trials ⋮ Pharmacokinetically guided optimum adaptive dose selection in early phase clinical trials ⋮ A Bayesian Phase I/II Trial Design for Immunotherapy ⋮ Time-to-event continual reassessment method incorporating treatment cycle information with application to an oncology phase I trial ⋮ Information in a two-stage adaptive optimal design ⋮ gBOIN‐ET: The generalized Bayesian optimal interval design for optimal dose‐finding accounting for ordinal graded efficacy and toxicity in early clinical trials ⋮ A Bayesian adaptive phase I/II clinical trial design with late‐onset competing risk outcomes ⋮ Adaptive Bayesian phase I clinical trial designs for estimating the maximum tolerated doses for two drugs while fully utilizing all toxicity information ⋮ A multi-armed Bayesian ordinal outcome utility-based sequential trial with a pairwise null clustering prior ⋮ A Bayesian adaptive dose-finding algorithm for balancing individual- and population-level ethics in Phase I clinical trials ⋮ Bayesian models and decision algorithms for complex early phase clinical trials ⋮ Bayesian phase I/II adaptively randomized oncology trials with combined drugs ⋮ Patient‐Specific Dose Finding Based on Bivariate Outcomes and Covariates ⋮ A new characterization of Elfving's method for high dimensional computation ⋮ A hybrid geometric phase II/III clinical trial design based on treatment failure time and toxicity ⋮ Incorporating Individual and Collective Ethics into Phase I Cancer Trial Designs ⋮ Adaptive designs for selecting drug combinations based on efficacy-toxicity response ⋮ Some geometric methods for constructing decision criteria based on two-dimensional parame\-ters ⋮ Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials ⋮ A Three-Stage Bayesian Adaptive Phase I/II Design and Simulation Studies ⋮ Simple benchmark for complex dose finding studies ⋮ Optimal design to discriminate between rival copula models for a bivariate binary response ⋮ A bargaining approach for resolving the tradeoff between beneficial and harmful drug responses ⋮ Sequential Methods in Multi-Arm Clinical Trials ⋮ escalation ⋮ Bayesian phase II adaptive randomization by jointly modeling time-to-event efficacy and binary toxicity ⋮ Correlated endpoints: simulation, modeling, and extreme correlations ⋮ A review of phase 2-3 clinical trial designs ⋮ Flexible link continual reassessment methods for trivariate binary outcome phase I/II trials ⋮ Using Joint Utilities of the Times to Response and Toxicity to Adaptively Optimize Schedule–Dose Regimes ⋮ Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios ⋮ A Bayesian adaptive design for addressing correlated late-onset outcomes in phase I/II randomized trials of drug combinations in oncology ⋮ trialr ⋮ A conversation with Nancy Flournoy ⋮ Rejoinder
Cites Work
- Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
- Dose-Finding Designs for HIV Studies
- Spherical-Radial Integration Rules for Bayesian Computation
- Selecting Therapeutic Strategies Based on Efficacy and Death in Multicourse Clinical Trials
- A Strategy for Dose-Finding and Safety Monitoring Based on Efficacy and Adverse Outcomes in Phase I/II Clinical Trials
- Approaches for Optimal Sequential Decision Analysis in Clinical Trials
- A Simplex Method for Function Minimization
- Unnamed Item
- Unnamed Item
This page was built for publication: Dose-Finding Based on Efficacy-Toxicity Trade-Offs
